Malaria prevention in infants may strengthen immunity for years

NCT ID NCT04978272

Ongoing Prevention Sponsor: Grant Dorsey, M.D, Ph.D. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial in Uganda tests whether giving young children monthly malaria prevention medicine (dihydroartemisinin-piperaquine) from 8 weeks to 1 or 2 years of age helps them develop stronger immunity against malaria later. 924 children are enrolled and followed until age 4. The goal is to see if early prevention reduces malaria cases after treatment stops, compared to no prevention.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dihydroartemisinin-piperaquine (DP)
What this could lead to: If successful, this could show that preventing malaria early in life helps children build stronger immunity, reducing infections later.
What could go wrong: This is a large trial but still early-stage for this specific approach. Results may not apply to other regions, and DP may cause side effects like nausea or heart rhythm changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA

Contacts and locations

Locations

IDRC - Tororo Research Clinic

Tororo, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.